

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit:

Examiner:

To be assigned

Atty. Docket: 1696.0020008/RWE/BEC

In re application of:

Shen et al.

Appl. No. 09/845,153

Filed:

May 1, 2001

For:

Methods and Compositions for

Lipidization of Hydrophilic

Molecules

# **Information Disclosure Statement**

Commissioner for Patents Washington, D.C. 20231

Listed on accompanying Form PTO-1449 are documents that may be considered Sir: material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. A copy of each of these documents is

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative provided. submits the following, in regards to non-English language documents AL1 and AR17 cited on Form PTO 1449:

Document AL1, a Japanese patent, is in a foreign language. No English translation is readily available. Document AR19 is provided as an English language abstract. Document AL1 appears to show 3-nitro-2-pyridyl-sulfenyl-L-cysteine.

Document AR17, a Japanese journal article, is in a foreign language. No English translation is readily available. Document AS17 is provided as an English language abstract. Document AR17 appears to show  $\gamma$ -glutamylcysteine- $\gamma$ -glutamylcysteine disulfide and the mixed disulfides: glutathione-cysteine, glutathione-3-mercaptolactate, glutathione- $\gamma$ -glutamylcysteine, and  $\gamma$ -glutamylcysteine-cysteine.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this pleading is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Bruce E. Challe

Bruce E. Chalker Agent for Applicants Registration No. 47,480

Date: August 23, 2001

1100 New York Avenue, N.W. Suite 600 Washington, D.C. 20005-3934 (202) 371-2600

P:\USERS\DENISEB\1696\0028ids SKGF Rev. 2/27/01 mac



### STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

ATTORNEYS AT LAW

HOO NEW YORK AVENUE, N.W. . WASHINGTON, D.C. 20005-3934

PHONE: (202) 371-2600 . FACSIMILE: (202) 371-2540 . www.skgf.com

OBERT W. ESMOND TRACY-GENE G. DURKIN MICHELE A. CIMBALA MICHAEL B. RAY ROBERT E. SOKOHL ERIC K. STEFFE ICHAEL Q. LEE STEVEN R. LUDWIG

JOHN M. COVERT LINDA E. ALCORN ROBERT C. MILLONIG MICHAEL V. MESSINGER JUDITH U. KIM TIMOTHY J. SHEA, JR. PATRICK E. GARRETT JEFFREY T. HELVEY HEIDI L. KRAUS JEFFREY R. KURIN PATRICK D. O'BRIEN LAWRENCE B. BUGAISKY CRYSTAL D. SAYLES

EDWARD W. YEE ALBERT L. FERRO\* DONALD R. BANOWIT PETER A. JACKMAN MOLLY A. MCCALL TERESA U. MEDLER JEFFREY S. WEAVER KENDRICK P. PATTERSON DONALD J. FEATHERSTONE VINCENT L. CAPUANO JOHN A. HARROUN\* ALBERT J. FASULO III ELDORA ELLISON FLOYD\*

W. RUSSELL SWINDELL THOMAS C. FIALA BRIAN J. DEL BUONO" VIRGIL L BEASTON\*
RYAN J. STAMPER\* REGINALD D. LUCAS\* THEODORE A. WOOD ELIZABETH J. HAANES BRUCE E. CHALKER KAREN R. MARKOWICZ\*\* SUZANNE E. ZISKA\*\* ANDREA J. KAMAGE\*\*
NANCY J. LEITH\*\*

MARK P JOSEPH N Douglas M ANN E. SUMMERFIELD\*\* CYNTHIA M. BOUCHEZ\*\* HELENE C. CARLSON\*\* GABY L. LONGSWORTH\*\* DUSTIN T. JOHNSON\*\* MATTHEW J. DOWD\*\* TIMOTHY M. SPEER\*\* AARON L. SCHWARTZ\*\*

\*LIMITED TO MATTERS AND PROCEEDINGS BEFORE
FEDERAL COURTS & AGENCIES
PREGISTERED PATENT AGENT \*\*\*SENIOR COUNSEL

> (202) 371-2630 **INTERNET ADDRESS:** bchalker@skgf.com

August 23, 2001

AUG 27 2001 TC 1700 WRITER'S DIRECT NUMBER:

Commissioner for Patents Washington, D.C. 20231

Re:

U.S. Utility Patent Application

Appl. No. 09/845,153; filed May 1, 2001

Methods and Compositions for Lipidization of Hydrophilic Molecules

Shen et al. Inventors:

Our Ref: 1696.0020008/RWE/BEC

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Information Disclosure Statement (in duplicate);
- Form PTO-1449 (22 sheets) and accompanying (74) references; and 2.
- 3. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents August 23, 2001 Page 2

AUG & 7 2001

TC 1700

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this letter is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Buce E. Chalher

Bruce E. Chalker Agent for Applicants Registration No. 47,480

BEC/dab
P:\USERS\DENISEB\1696\0028idscov
Enclosures

### UFCFIAFO

AUG 2 8 2001

**TECH CENTER 1600/2900** 

Page 1 of 22

FORM PTO-1449

### INFORMATION DISCLOSURE STATEMENT

APPLICATIONO 09/845,153 ATTY. DOCKET NO. 1696.0020008/RWE/BEC APPLICANTS Shen et al. GROUP FILING DATE

INF	ORMATION	DISCL	OSURE STA	<u>rement</u>	FILING DATE		GROUP	ے مناوت	2001
					May 1, 2001 PATENT DOCUMENTS			- 1	1700
				U.S.	PATENT DOCUMENTS	T			T 1 00
EXAMINER INITIAL		DOCUM		DATE	NAME	CL	ASS	SUB- CLASS	FILING DATE
	AA1	5,599		02/04/1997	Kauvar et al.	53	0	331	09/24/1993
	AB1		,020	05/13/1997	Leone-Bay et al.	42	4	489	04/22/1994
	AC1	5,635		06/03/1997	Naftilan et al.	43	5	172.3	01/18/1994
	AD1	5,679		10/21/1997	Kauvar et al.	51	4	18	05/31/1994
	AE1	+	3,146	01/13/1998	Willner et al.	53	0	387.3	06/06/1995
	AF1		3,570	06/09/1998	Kauvar et al.	53	0	331	06/07/1995
	AG	3,.55				$\perp$			
	AH	+							
	AI	<del> </del>							
	AJ	<del>                                     </del>							
		<del> </del>							
	AK			FOREIG	N PATENT DOCUMENTS				
EXAMINER INITIAL		DOCU		DATE	COUNTRY	CI	ASS	SUB- CLASS	TRANSLATION
	AL1	NUMB	3246382	10/13/1988	Japan				Abstract Yes No
	AM1		1/16067	10/31/1991	WIPO				Yes No
	AN1		482 766	04/29/1992	Europe				Yes No
	AO1		6/22773	08/01/1996	WIPO				Yes No
		1,,,,,,							Yes No
	AP			1 11 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -	, Title, Date, Pertinent Pa	ages,	etc.)		
		1	OTHER (Inc	luding Author,	, litte, Date, 1920				
	AR	1	Culture. Transport Epithelia	II: Effect of	gnusson, C., "Epithelial T Extracellular Calcium Con Different Lipophilicities lls," <i>J. Pharm. Sci</i> . 79:59	acros	s Mon	olavers o	f Intestinal
	AS Broadwell, R.D., et al., "Transcytotic pathway for blood-borne protein through the blood-brain barrier," Proc. Natl. Acad. Sci. USA 85:632-636, National Academ of Sciences (1988).								
	AT	1	Latex."	ırst, K., et a Biochem. J. 13 cal Society (1	al., "Preparation of Fully 33:573-584, London Portland	Acti l Pre	ve Pap ss On	ain From Behalf Oi	Dried Papaya The
EVANTNED		<u> </u>	<u> </u>			DA	TE CON	SIDERED	
EXAMINER								ngo with	MDED 609 Dray

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

AUG 2 8 2001

THE COUNTRY DOCUMENTS  AND 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2					OIPE			TECL	TECH CENTER 1699/2986 22		
U.S. DATENT DOCUMENTS  CLASS SUB-					Line -	ATTY. DOCKET NO. 21696.0020008/RWE	E/BEC		CATTON NO		
U.S. DATENT DOCUMENTS  CAMINER NAME  CLASS SUB- CLASS S		F	ORM PT	0-1449	3	, ~ [	E '	. =	<u>.</u>		
U.S. DATENT DOCUMENTS  U.S. DATENT DOCUMENTS  CLASS SUB- CLASS SUB	TNF	OTTAMEO	1 DISC	LOSURE STA	ATEMONT COMP		AUG	2 7 200	1		
TAMINER  DOCUMENT NUMBER  DATE NAME  CLASS SUBCLASS  FILING DATE  AA  AB  AB  AC  AD  AC  AD  AB  AG  AG  AG  AI  AI  AI  AI  AI  AI  AI	<u> 1414                                 </u>	<u> </u>			THAUL			1646			
DOUMENT DATE NAME CLASS SUB-FILING DATE NAME  AA AA AB AB AB AC									U		
DOCUMENT NUMBER  AA  AB  AB  AC  AC  AC  AF  AF  AG  AR  AF  AG  AR  AF  AG  AR  AN  AN  BOCUMENT  AR  AN  AN  AN  AN  AN  COUNTRY  CLASS  SUB- CLASS  TRANSLATIC CLASS  TRANS					U.S.	PATENT DOCUMENTS			1	1	
AB  AC  AC  AC  AC  AC  AC  AC  AC  AC					DATE	NAME		CLASS		FILING DATE	
AC AD AD AD AD AP OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  AR 2 Chu, YC., et al., "High-Potency Hybrid Compounds Related to Insulin and Amphicous Insulin-like Peptide," Blochem. 33:13087-13092, American Chemical Society (1994).  EXAMINER  DATE CONSIDERED  CLASS SUB-CLASS  TRANSLATIC  CLASS SUB-CLASS  TRANSLATIC  CLASS SUB-CLASS  TRANSLATIC  TRANSLATIC  CLASS SUB-CLASS  TRANSLATIC  TRANSLATIC  CLASS SUB-CLASS  TRANSLATIC  TRANSLAT		AA			ļ				<del>                                     </del>		
AD  AE  AF  AF  AG  AH  AI  AI  AJ  AX  FOREIGN PATENT DOCUMENTS  XAMINER NITIAL  DOCUMENT NUMBER  AL  AM  AN  AN  AN  AN  AN  AN  AN  AN  AN		AB									
AE  AF  AG  AG  AH  AI  AJ  AX  FOREIGN PATENT DOCUMENTS  XXMININER NITIAL  DOCUMENT NUMBER  AL  AM  AN  AN  AN  AN  AN  AN  AN  AN  AN		AC			<u> </u>			<del>                                     </del>	<del> </del>		
AF AG AH AH AI		AD			<u> </u>				<del> </del>		
AG  AH  AI  AI  AJ  AJ  AK  POREIGN PATENT DOCUMENTS  XAMINER NITIAL  DOCUMENT NUMBER  DATE  COUNTRY  CLASS SUB- CLASS CLASS  TRANSLATI CLASS  AB  AN  AN  AN  AN  AN  AN  AN  AN  AN		AE									
AH AI AI AI AJ AK FOREIGN PATENT DOCUMENTS  XAMINER NITIAL DOCUMENT DATE COUNTRY CLASS SUBCLASS TRANSLATIC CLASS AMINER NITIAL AL AMINER (Including Author, Title, Date, Pertinent Pages, etc.)  AR 2 Chekhonin, V.P., et al., "Fatty acid acylated Fab-fragments of antibodies to neurospecific proteins as carriers for neuroleptic targeted delivery in brain," FEBS Letters 287:149-152, Elsevier Science Publishers B.V. (1991).  AS 2 Chu, YC., et al., "High-Potency Hybrid Compounds Related to Insulin and Amphioxus Insulin-like Peptide," Biochem. 33:13087-13092, American Chemical Society (1994).  EXAMINER Initial if reference considered, whether or not citation is in conformance with MPER 609. Time through citation if not in conformance and not considered. Include copy of this form with next		AF						<del> </del>	<del>                                      </del>		
AI AJ AJ AK  FOREIGN PATENT DOCUMENTS  KAMINER NITIAL DOCUMENT DATE COUNTRY CLASS SUB-CLASS TRANSLATIC CLASS CLASS TRANSLATIC CLASS AM AM AN		AG							<del> </del>		
AMMINER NITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION NUMBER CLASS OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  AR 2 Chekhonin, V.P., et al., "Fatty acid acylated Fab-fragments of antibodies to neurospecific proteins as carriers for neuroleptic targeted delivery in brain," FEBS Letters 287:149-152, Elsevier Science Publishers B.V. (1991).  AS 2 Chu, YC., et al., "High-Potency Hybrid Compounds Related to Insulin and Amphioxus Insulin-like Peptide," Biochem. 33:13087-13092, American Chemical Society (1994).  EXAMINER  EXAMINER  EXAMINER  EXAMINER  DATE CONSIDERED		AH						<b> </b>		-	
FOREIGN PATENT DOCUMENTS  XAMINER NITIAL  DOCUMENT DATE COUNTRY  CLASS SUBCLASS  TRANSLATIC CLASS  AL  AM  AN  AN  OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  Chekhonin, V.P., et al., "Fatty acid acylated Fab-fragments of antibodies to neurospecific proteins as carriers for neuroleptic targeted delivery in brain," FFBS Letters 287:149-152, Elsevier Science Publishers B.V. (1991).  AS 2 Chu, YC., et al., "High-Potency Hybrid Compounds Related to Insulin and Amphioxus Insulin-like Peptide," Biochem. 33:13087-13092, American Chemical Society (1994).  EXAMINER  EXAMINER  DATE CONSIDERED  EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. The protect of the policy of this form with next		AI							+	+	
XAMINER NITIAL DOCUMENT DATE COUNTRY CLASS SUB-TRANSLATIC CLASS TRANSLATIC CLASS SUB-TRANSLATIC CLASS SUB-TRANSLAT		AJ						<u> </u>	<del> </del>	+	
AMINER NITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION NUMBER CLASS SUBCLASS TRANSLATION NUMBER CLASS SUBCLASS TRANSLATION NUMBER CLASS SUBCLASS TRANSLATION NUMBER CLASS SUBCLASS SUBCLASS TO SUBCLASS SUBCLAS		AK									
AL  AM  AN  AN  AN  AN  AN  AN  AN  AN  AN					FOREI	GN PATENT DOCUMENTS	s	<del></del>		1	
AL  AM  AN  AN  AN  AN  AP  OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  Chekhonin, V.P., et al., "Fatty acid acylated Fab-fragments of antibodies to neurospecific proteins as carriers for neuroleptic targeted delivery in brain," FEBS Letters 287:149-152, Elsevier Science Publishers B.V. (1991).  AS 2 Chu, YC., et al., "High-Potency Hybrid Compounds Related to Insulin and Amphioxus Insulin-like Peptide," Biochem. 33:13087-13092, American Chemical Society (1994).  AT 2 Chu, YC., et al., "High-Potency Hybrid Compounds Related to Insulin and Amphioxus Insulin-like Peptide," Chem. Abstracts 121:212, Abstract No. 2465829 American Chemical Society (November 1994).  EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. line through citation if not in conformance and not considered. Include copy of this form with next	EXAMINER INITIAL		DOCOME		DATE	COUNTRY		CLASS		TRANSLATIO	
AM  AN  AO  AP  OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  Chekhonin, V.P., et al., "Fatty acid acylated Fab-fragments of antibodies to neurospecific proteins as carriers for neuroleptic targeted delivery in brain," FEBS Letters 287:149-152, Elsevier Science Publishers B.V. (1991).  AS 2 Chu, YC., et al., "High-Potency Hybrid Compounds Related to Insulin and Amphioxus Insulin-like Peptide," Biochem. 33:13087-13092, American Chemical Society (1994).  AT 2 Chu, YC., et al., "High-Potency Hybrid Compounds Related to Insulin and Amphioxus Insulin-like Peptide," Chem. Abstracts 121:212, Abstract No. 2465829 American Chemical Society (November 1994).  EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. In through citation if not in conformance and not considered. Include copy of this form with next										Ye	
AN  AD  OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  Chekhonin, V.P., et al., "Fatty acid acylated Fab-fragments of antibodies to neurospecific proteins as carriers for neuroleptic targeted delivery in brain," FEBS Letters 287:149-152, Elsevier Science Publishers B.V. (1991).  AS  Chu, YC., et al., "High-Potency Hybrid Compounds Related to Insulin and Amphioxus Insulin-like Peptide," Biochem. 33:13087-13092, American Chemical Society (1994).  Chu, YC., et al., "High-Potency Hybrid Compounds Related to Insulin and Amphioxus Insulin-like Peptide," Chem. Abstracts 121:212, Abstract No. 2465829 American Chemical Society (November 1994).  EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Inic through citation if not in conformance and not considered. Include copy of this form with next		AL						+		Ye	
AN  AD  OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  Chekhonin, V.P., et al., "Fatty acid acylated Fab-fragments of antibodies to neurospecific proteins as carriers for neuroleptic targeted delivery in brain," FEBS Letters 287:149-152, Elsevier Science Publishers B.V. (1991).  AS 2 Chu, YC., et al., "High-Potency Hybrid Compounds Related to Insulin and Amphioxus Insulin-like Peptide," Biochem. 33:13087-13092, American Chemical Society (1994).  AT 2 Chu, YC., et al., "High-Potency Hybrid Compounds Related to Insulin and Amphioxus Insulin-like Peptide," Chem. Abstracts 121:212, Abstract No. 2465829 American Chemical Society (November 1994).  EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Inite through citation if not in conformance and not considered. Include copy of this form with next					1	li di					
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  AR 2 Chekhonin, V.P., et al., "Fatty acid acylated Fab-fragments of antibodies to neurospecific proteins as carriers for neuroleptic targeted delivery in brain," FEBS Letters 287:149-152, Elsevier Science Publishers B.V. (1991).  AS 2 Chu, YC., et al., "High-Potency Hybrid Compounds Related to Insulin and Amphioxus Insulin-like Peptide," Biochem. 33:13087-13092, American Chemical Society (1994).  Chu, YC., et al., "High-Potency Hybrid Compounds Related to Insulin and Amphioxus Insulin-like Peptide," Chem. Abstracts 121:212, Abstract No. 2465829 American Chemical Society (November 1994).  EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.		AM _	+							Y	
AP  OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  AR 2 Chekhonin, V.P., et al., "Fatty acid acylated Fab-fragments of antibodies to neurospecific proteins as carriers for neuroleptic targeted delivery in brain," FEBS Letters 287:149-152, Elsevier Science Publishers B.V. (1991).  AS 2 Chu, YC., et al., "High-Potency Hybrid Compounds Related to Insulin and Amphioxus Insulin-like Peptide," Biochem. 33:13087-13092, American Chemical Society (1994).  Chu, YC., et al., "High-Potency Hybrid Compounds Related to Insulin and Amphioxus Insulin-like Peptide," Chem. Abstracts 121:212, Abstract No. 2465829 American Chemical Society (November 1994).  EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. In through citation if not in conformance and not considered. Include copy of this form with next		AN								- Y	
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  Chekhonin, V.P., et al., "Fatty acid acylated Fab-fragments of antibodies to neurospecific proteins as carriers for neuroleptic targeted delivery in brain," FEBS Letters 287:149-152, Elsevier Science Publishers B.V. (1991).  AS 2 Chu, YC., et al., "High-Potency Hybrid Compounds Related to Insulin and Amphioxus Insulin-like Peptide," Biochem. 33:13087-13092, American Chemical Society (1994).  EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. The property of this form with next in the property of this form with next in the property of this form with next in the pages, etc.)  Chu, YC., et al., "High-Potency Hybrid Compounds Related to Insulin and Amphioxus Insulin-like Peptide," Chem. Abstracts 121:212, Abstract No. 2465829 American Chemical Society (November 1994).								ł	1		
Chekhonin, V.P., et al., "Fatty acid acylated Fab-fragments of antibodies to neurospecific proteins as carriers for neuroleptic targeted delivery in brain,"  FEBS Letters 287:149-152, Elsevier Science Publishers B.V. (1991).  Chu, YC., et al., "High-Potency Hybrid Compounds Related to Insulin and Amphioxus Insulin-like Peptide," Biochem. 33:13087-13092, American Chemical Society (1994).  AT 2 Chu, YC., et al., "High-Potency Hybrid Compounds Related to Insulin and Amphioxus Insulin-like Peptide," Chem. Abstracts 121:212, Abstract No. 2465829 American Chemical Society (November 1994).  EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. The provided of the provided copy of this form with next in the position of the provided copy of this form with next in the provided copy of this form with next in the provided copy of this form with next in the provided copy of this form with next in the provided copy of this form with next in the provided copy of this form with next in the provided copy of this form with next in the provided copy of this form with next in the provided copy of this form with next in the provided copy of this form with next in the provided copy of this form with next in the provided copy of this form with next in the provided copy of this form with next in the provided copy of this form with next in the provided copy of this form with next in the provided copy of this form with next in the provided copy of this form with next in the provided copy of the provided copy of the provided copy of this form with next in the provided copy of		AO								Y	
Chekhonin, V.P., et al., "Fatty acid acylated Fab-fragments of antibodies to neurospecific proteins as carriers for neuroleptic targeted delivery in brain,"  FEBS Letters 287:149-152, Elsevier Science Publishers B.V. (1991).  Chu, YC., et al., "High-Potency Hybrid Compounds Related to Insulin and Amphioxus Insulin-like Peptide," Biochem. 33:13087-13092, American Chemical Society (1994).  Chu, YC., et al., "High-Potency Hybrid Compounds Related to Insulin and Amphioxus Insulin-like Peptide," Chem. Abstracts 121:212, Abstract No. 2465829 American Chemical Society (November 1994).  EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. The provided of the provided copy of this form with next in the provided copy of this form with next in the provided copy of this form with next in the provided copy of this form with next in the provided copy of this form with next in the provided copy of this form with next in the provided copy of this form with next in the provided copy of this form with next in the provided copy of this form with next in the provided copy of this form with next in the provided copy of this form with next in the provided copy of this form with next in the provided copy of this form with next in the provided copy of this form with next in the provided copy of this form with next in the provided copy of this form with next in the provided copy of this form with next in the provided copy of the			İ								
Chekhonin, V.P., et al., "Fatty acid acylated Fab-fragments of antibodies to neurospecific proteins as carriers for neuroleptic targeted delivery in brain," FEBS Letters 287:149-152, Elsevier Science Publishers B.V. (1991).  AS 2 Chu, YC., et al., "High-Potency Hybrid Compounds Related to Insulin and Amphioxus Insulin-like Peptide," Biochem. 33:13087-13092, American Chemical Society (1994).  AT 2 Chu, YC., et al., "High-Potency Hybrid Compounds Related to Insulin and Amphioxus Insulin-like Peptide," Chem. Abstracts 121:212, Abstract No. 2465829 American Chemical Society (November 1994).  EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. The property of this form with next in through citation if not in conformance and not considered. Include copy of this form with next		AP			aluding Author	ritle, Date, Per	tinent Pag	ges, etc.	)		
AR 2 neurospecific proteins as Carriers for Neurospecific Publishers B.V. (1991).  AS 2 Chu, YC., et al., "High-Potency Hybrid Compounds Related to Insulin and Amphioxus Insulin-like Peptide," Biochem. 33:13087-13092, American Chemical Society (1994).  Chu, YC., et al., "High-Potency Hybrid Compounds Related to Insulin and Amphioxus Insulin-like Peptide," Chem. Abstracts 121:212, Abstract No. 2465829 American Chemical Society (November 1994).  EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. The property of this form with next line through citation if not in conformance and not considered. Include copy of this form with next			_	THER (III	cluding Ruene.			<u> </u>			
Amphioxus Insulin-like Peptide, "Blochem. 33.1300, 1302, Manchem Society (1994).  Chu, YC., et al., "High-Potency Hybrid Compounds Related to Insulin and Amphioxus Insulin-like Peptide, "Chem. Abstracts 121:212, Abstract No. 246582y American Chemical Society (November 1994).  EXAMINER  EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. The proof of this form with next in through citation if not in conformance and not considered. Include copy of this form with next		AR	2							bodies to y in brain,"	
Amphioxus Insulin-like Peptide, "Chem. Abstracts 127.00, American Chemical Society (November 1994).  EXAMINER  EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.  Line through citation if not in conformance and not considered. Include copy of this form with next		AS	2	Amphiox	ıs Insulin-lik	High-Potency Hybrice Peptide," <i>Bioche</i>	d Compound m. 33:1308	ls Related 7-13092,	i to Insul American	in and Chemical	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. It is through citation if not in conformance and not considered. Include copy of this form with next		AT	2	14 lambiovus Insulin-like Peptide, " Chem. Abstracts 121.222, 121.							
<b>EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609.								DATE CO	NSIDERED		
line through citation if not in conformance and not constants						N	tion is in	conform	ance with	MPEP 609. I	
communication to Applicant.	line thro	ugh cita	ation	if not in	conformance a	and not considered.	Include	copy of	this form	with next	
Communication of the	communica	tion to	Appli	cant.							

1005 8 2 DUA TECH CENTER 1600/2900

Page 3 of 22

ATTY. DOCKET NO. 1696.0020008/RWE/BEC APPLICANTS

APPLICATION NO. 09/845,153 AUG 2 7 2001

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

Shen et al. T GROW 700 FILING DATE

				<b>U</b> .5	. PATENT DOCUMENTS				
KAMINER NITIAL		DOCUM		DATE	NAME	CLASS	SUB- CLASS	FILING DATE	
	<del></del>	NUMBE	SR						
	AA	<del> </del>		<del> </del>					
	AB	+							
	AC	+		<del> </del>					
	AD	+							
	AE AF	<del> </del>							
	AG	<del> </del>							
	AH	+					<b> </b>		
	AI							<del> </del>	
	AJ	1					<u> </u>		
	AK	1							
	AK			FOR	EIGN PATENT DOCUMENTS				
EXAMINER INITIAL			MENT	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
		NUME	SER					Yes No	
	AL	+		1				Yes	
	AM						+	Yes	
								No	
	AN			<del> </del>				Yes	
	AO							No.	
								Ye:	
	AP			L					
			OTHER (In	cluding Autl	nor, Title, Date, Pertin	ent Pages, etc.			
	AR	3	Conradi,	R.A., et a Cells," Phar	l., "The Influence of Pe m. Res. 8:1453-1460,Plei	eptide Structure num Publishing C	on Trans	port Across	
	AS	3	Edwards, P.A.W., "Is Mucus a Selective Barrier to Macromolecules?" British Med. Bulletin 34:55-56, British Council, Medical Dept. (1978).						
		3	Ekrami, H.M., "Positively-charged and lipophilic Bowman-Birk Protease Inhibitor conjugates: Synthesis and Characterization of the Pharmaceutical and Chemopreventive properties," A Dissertation, UMI Dissertation Services, Ann Arbor, MI, i-xiii, 9-226 (after January 25, 1995)						
	AT		Chemopr Arbor,	MI, i-xiii,	9-226 (after January 25	5, 1995)			

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

STATE TRAD

# RECEIVED

AUG 2 8 2001 APARCH CENTER 4800 2900 2 09/845

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

Y. DOCKET NO. 1696.0020008/RWE/BEC

APPLICANTS Shen et al.

AUG 250000001

FILING DATE May 1, 2001 U.S. PATENT DOCUMENTS FILING DATE EXAMINER CLASS SUB-NAME DOCUMENT DATE CLASS INITIAL NUMBER AΑ AB АÇ ΑD ΑE ΑF AG AΗ ΑI ΑJ ΑK FOREIGN PATENT DOCUMENTS TRANSLATION EXAMINER SUB-CLASS COUNTRY DATE DOCUMENT TNITIAL CLASS NUMBER Yes No ΑL Yes No AM Yes No ΔN Yes No ΑO Yes No ΑP OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Ekrami, H.M., et al., "Water-soluble fatty acid derivatives as acylating agents for reversible lipidization of polypeptides," FEBS Letters 371:283-286, Federation of European Biochemical Societies (1995). AR 4 Ekrami, H.M., et al., "Water-soluble fatty acid derivatives as acylating agents for reversible lipidization of polypeptide, "Chem. Abstracts 124:1042, Abstract AS 4 No. 30361q, American Chemical Society (1996). Eriksson, S.A., and Mannervik, B., "A method for the direct recording of an enzyme-catalyzed thiol-disulfide interchange using mixed disulfide of glutathione and 3-carboxy-4-nitrobezenethiol, Biochim. Biophys. Acta 212:518-520, Elsevier ТΑ <u>4</u> Publishing Co. (1970). DATE CONSIDERED EXAMINER

Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

## AUG 2 8 2001 TECH CENTER 1600/2900

Page 5 of 22

### FORM PTO-1449

### INFORMATION DISCLOSURE STATEMENT

DOCKET NO. 1696.0020008/RWE/BEC

APPLICATION NO. 09/8457193/ APPLICANTS

Shen et al. FILING DATE AUG 2001 1646

	10 11 1				May 1, 2001	1646	-700			
		====		υ.:	S. PATENT DOCUMENTS	101	<u> //UD</u>	T		
AMINER		DOCUME		DATE	NAME	CLASS	SUB- CLASS	FILING DATE		
	AA	1101.22	·				<b></b>			
	AB						<del> </del>	<del> </del>		
	AC	<del>                                     </del>					<del> </del>			
	AD									
	AE						<del> </del>	+		
	AF	1								
	AG	1								
	AH									
	AI	<del>                                     </del>						+		
	AJ	1						+		
	AK	1					<u> </u>			
	AK			FOR	REIGN PATENT DOCUMENTS			<del></del>		
XAMINER NITIAL		DOCU		DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION		
	_	NUMBI	ER					Ye:		
	AL			<del></del>				Ye.		
	AM		_					Ye		
								N		
	AN							Ye		
		1		l l				N		
	AO							Ye N		
	AP	1		<u> </u>						
			THER (In	cluding Aut	hor, Title, Date, Pert	inent Pages, etc.	<u>)                                    </u>			
	AR	<u>5</u>	Eriksson disulfic nitrobe Society	de interchar zenethiol,"	annervik, B., "Direct r nge using a mixed disul Chem. Abstracts 73:39,	ecording of an enfide of glutathic Abstract No. 12	nzyme-cata one and 3- 7175y, Ame	alyzed thiol- carboxy-4- erican Chemica		
	AS	<u>5</u>	gastroi	Fix, J.A., et al., "Acylcarnitines: drug absorption-enhancing agents in the gastrointestinal tract," $Am.\ J.\ Physiol.\ 251:G332-G340$ , American Physiological Society (1986).						
		1			Walus, L.R., "Transpor	t Of Proteins Acr	coss the B	lood-Brain		
	AT	<u>5</u>	Barrie	via the Tr	Walus, L.R., "Transpor cansferrin Receptor," I and Its Regulation, L w York, USA. pp.129-1	.R. Drewes and A.	L. Betz,	eds. Plenum		

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

AUG 2 8 2001

F. TECH CENTEB 1600/29002

AUG 2 3 2001

TRADEM

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1696.0020008/RWE/BEC

APPLICANTS Shen et al.

FILING DATE

INF	ORMATION	DIOGE			FILING DATE May 1, 2001	1646	703	
				v.s	. PATENT DOCUMENTS		<del></del>	
KAMINER NITIAL		DOCUM NUMBE		DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						<del> </del>	
	AB						<del> </del>	
	AC							
	AD						<del> </del>	
	AE							
	AF							
	AG						+	
	АН							
	AI							
	АJ						<del>                                     </del>	
	AK							
				FORE	IGN PATENT DOCUMENTS			
EXAMINER INITIAL		DOCU		DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
		NUMB	ER					Ye:
	AL							Ye
	AM							Ye
								N
	AN	-						Ye N
	AO							Ye
	AP	İ						N
	I AF		OTUED (T	ncluding Autho	or, Title, Date, Perti	nent Pages, etc.	)	
	AR	<u>6</u>	Gonzale Cells (	z-Mariscal, L MDCK)," J. Me	., et al., "Tight Junc mbrane Biol. 86:113-12	etion Formation i 15, Springer-Verl	n Culture	ed Epithelial
	AS	<u>6</u>	bile sa	G.S., et al. alts," <i>Proc. N</i> es (1985).	, "Nasal absorption of Jatl. Acad. Sci. USA 82	f insulin: Enhan 2:7419-7423, Nat:	cement by ional Acad	hydrophobic demy of
	AT	<u>6</u>	Hashim Biolog	oto, M., et a ical Activitie	l., "Synthesis of Palm es," <i>Pharm. Res. 6</i> :171	itoyl Derivative -176 Plenum Pres	s of Insu s (1989).	lin and Their
			<u> </u>			DATE CO	NSIDERED	
EXAMINER						on is in conform		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

AUG 2 8 2001

AUS 2 7 TECH CENTER 1600/2900

FORM PTO-1449

### INFORMATION DISCLOSURE STATEMENT

APPLICATION NO. ATTY. DOCKET NO. 1696.0020008/RWE/BEC APPLICANTS Shen et al. GROUP FILING DATE

					May 1, 2001	1646		
				U.S.	PATENT DOCUMENTS			
EXAMINER INITIAL		DOCU NUMB		DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						<del>-</del>	
	AB							
	AC						<u> </u>	
	AD	ļ						
	AE	<u> </u>					<del>                                     </del>	
	AF						-	
	AG	<del> </del>						
	AH	-				<del></del>		
	AI	<del> </del>						
	AJ							
	AK	<u></u>		<u> </u>				
·	<del></del>			FOREI	GN PATENT DOCUMENTS	· · · · · · · · · · · · · · · · · · ·		
EXAMINER INITIAL	ļ	DOCU	MENT BER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL							Yes No
	2.14	ŀ						Yes No
	AM							Yes No
	AN							Yes No
	AO							Yes No
	AP			leading leading	, Title, Date, Pertinent	Pages, etc.)		
	AR	7		, et al., "Li and Syntheti	pophilic Multiple Antigen c Vaccine," <i>Mol. Immunol</i>	n Pentide Sys	stem for 1	Peptide ier Science
	AS	7	Conjugate	e.A., et al., es of Morphine on (1991).	"Lipidic Peptides. III: : e," <i>J. Pharm. Sci. 80:</i> 110	Lipidic Amin 3-1105, Amer	o Acid and ican Phar	d Oligomer maceutical
	AT	7	Conjugate	s with Increa	"Lipidic Peptides. V: Pe ased Lipophilic Character al Association (1992).	nicillin and ," J. Pharm.	Cephalos Sci. 81:	porin Acid 845-848,
EXAMINER		<u> </u>	<u></u>			DATE CON	SIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

AUG 2 7 2001

AUG 2 8 2001

Y. DOCKET NO. 1696.0020008/RWE/BEC TECH CENTER 600/2000 09/845,153

FORM PTO-1449

APPLICANTS Shen et al.

		<b></b>	corme cm:	A TO THE MENT	Shen et al.					
INF	ORMATION	DISCL	OSURE STA	TEMENT	FILING DATE May 1, 2001	GROUP 1646	· ————			
				<b>U.</b> S	. PATENT DOCUMENTS					
XAMINER NITIAL		DOCUM:		DATE	NAME	CLASS	SUB- CLASS	FILING DATE		
	AA						+			
	AB						<del> </del>			
	AC						+			
	AD	Ι					+			
	AE			<b></b>			<del>                                     </del>	+		
	AF						+	+		
	AG						+			
	AH						<del></del>			
	AI						+			
	AJ			<del></del>						
	AK									
				FORE	EIGN PATENT DOCUMENTS					
EXAMINER INITIAL		DOCU		DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION		
		NUMB	EK	+				Yes		
	AL							Ye		
		1			_			Ye N		
	AM							Ye		
		1		1				М		
	AN_	+		+				Ye N		
	AO _							Ye		
		1						Ye N		
	AP					Pages etc.	\ \			
			OTHER (In	cluding Auth	or, Title, Date, Pertine	ent Payes, co.	<u>'</u>			
	AR	8	Inagaki, human na (1985).	, M., et al., isal mucosa,'	, "Macromolecular permeal " Rhinology 23:213-221,	bility of the t International F	ight junc	tion of the Society		
	AS	<u>8</u>	Kabanov transpo	, A.V., et a rt," Protein	1., "Lipid modification Engineering 3:39-42, IR	of proteins and RL Press (1989)	d their mo	embrane		
1			+	Kajii, H., et al., "Fluorescence Study on the Interaction of Salicylate with Rat Small Intestinal Epithelial Cells: Possible Mechanism for the Promoting Effects of Salicylate on Drug Absorption <u>In Vivo</u> ," <i>Life Sci</i> . 37:523-530, Pergamon Press Ltd. (1985).						
	AT	8	Small I of Sali	ntestinal Ep cylate on Dr	"Fluorescence Study on to ithelial Cells: Possible ug Absorption <u>In Vivo</u> ,"	Life Sci. 37:5	of Salic the Prom 323-530, P	ylate with Ra oting Effects ergamon Press		

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. line through citation if not in conformance and not considered. Include copy of this form with next Draw communication to Applicant.

AUG 2 8 2000 PECH CENTER 1600/2909 7 2007

FORM PTO-1449

### INFORMATION DISCLOSURE STATEMENT

Page 9 of 22
ATTY. DOCKET NO. 1 ADDITION NO. 1696.0020008/RWE/BEC 1 445,153

APPLICANTS
Shen et al.

FILING DATE

GROUP

<del></del>					May 1, 2001		1646		
				пс	PATENT DOCUMENTS				
EXAMINER INITIAL		DOCUM		DATE	NAME		CLASS	SUB- CLASS	FILING DATE
		NUMBE	R						
	AA	<del> </del> -							
	AB	<del>                                     </del>							
	AC								
	AD	<del> </del>							
	AE	+							<u> </u>
	AF	╅							
	AG								
	AH	+							
	AI	+							
	AJ	<del></del>							
	AK			FOREI	GN PATENT DOCUMENTS				<del></del>
EXAMINER INITIAL		DOCU		DATE	COUNTRY		CLASS	SUB- CLASS	TRANSLATION
		NUMB	ER						Yes
	AL								No
		1							Yes No
	AM								Yes
	<u> </u>			ļ					No
	AN	+							Yes
	AO								No Yes
									No.
	AP					Bass	o oto	\	
			THER (In	cluding Author	, Title, Date, Pertir	nent Page	ss, ecc.	<u>′                                    </u>	
	AR	9	Kamagami liposoma Abstract	, S., et al., lly entrapped s 114:457 Abs	"Penetration enhance drugs using N,N'-dia tract No. 214316d, Am	ment acre cylcysti erican C	oss a mo ne as a hemical	del membr bilayer l Society (	ane by ipid," Chem. 1991).
	AS	9	Kidron, Intestir	M., et al., " ee," Life Sci.	The Absorption of Ins 31:2837-2841, Pergam	sulin fro non Press	om Variou	ıs Regions 1982).	of the Rat
	AT	9	or acyl	H., et al., 'peptides as dione into the	Application of synthedrug carriers. I. Theil liver, "Chem. Abstraces).	etic lipo ir prepar cts 107:	osomes b cation a Abstrac	ased on ac nd transpo t No. 1834	cyl amino acids ort of 193h, American
							DATE CO	NSIDERED	
EXAMINER									MDED 609 Dray

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

# RECEIVED All G 2 8 2001

AUG 2 7 2/TECH CENTER 1600/2900

FORM	PTO-144	9

### INFORMATION DISCLOSURE STATEMENT

APPLICATION NO. ATTY. DOCKET NO. 1696.0020008/RWE/BEC APPLICANTS Shen et al. GROUP FILING DATE

					FILING DATE May 1, 2001_		1646		
						mc			
				<u> </u>	. PATENT DOCUMENT	TS	Γ		
EXAMINER INITIAL		DOCUI NUMBI		DATE	NAME		CLASS	SUB- CLASS	FILING DATE
	AA						<del> </del>	<del> </del>	<del> </del>
	AB						<del> </del>	<del>                                      </del>	<del> </del>
	AC						<u> </u>		<del> </del>
	AD						<del> </del>	<del>                                       </del>	<del>   </del>
	AE							<del> </del>	
	AF				_			<del> </del>	
	AG						<del> </del>	<del>                                     </del>	-
	AH						<del> </del>	<del> </del>	
	AI						<del>                                      </del>	<del> </del>	+
	AJ						<del> </del>	<del>                                      </del>	
	AK							<u> </u>	
				FORE	IGN PATENT DOCUM	ents		<del></del>	T
EXAMINER INITIAL		DOCU	JMENT BER	DATE	COUNTRY		CLASS	SUB- CLASS	TRANSLATION
		1							Yes No
	AL	+							Yes No
	AM	-						+	Yes
	AN							<del> </del>	No Yes
	AO							<u> </u>	No No
		1							Yes No
	AP		(Ind	luding Autho	or, Title, Date,	Pertinent Pac	res, etc.)		
		<del></del>							
	AR	10	Fibroblas Evolution Transform	sts: Historic n and Optimi: mation Assay	mical Transformat cal Background, A zation of the Tra of Established ( saki, eds. IARC ( for Research on	Assessment of ansformation <i>i</i> Cell Lines: Mo Scientific Pui	the Irans Assay Prot echanisms blications	tocol," In and Appli	ication, "T.
	AS	10	Lee, V.H	.L., "Enzyma ug Carrier S	tic Barriers to l Syst. 5:69-97, CR	Peptide and P C Press, Inc.	rotein Ab: (1988).	sorption,	' Crit. Rev.
	AT	10	and Prote	.L., et al., ein Drug Abs nc. (1991).	"Mucosal Penetr corption," <i>Crit</i> .	ation Enhance Rev. Ther. Dr	rs for Fa ug Carrie	cilitation or Syst. 8	ı of Peptide :91-192, CRC
EXAMINER							DATE CON	SIDERED	
li .									

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. line through citation if not in conformance and not considered. Include copy of this form with next Draw communication to Applicant.

TA TRADE

LICEIVED AUG 2 8 2001

TECH CENTER 1600/2900

APPLICATION NO.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1696.0020008/RWE/BEC

APPLICANTS Shen et al.

FILING DATE May 1, 2001

GROUP 1646

09/845,153

1700

					May 1, 2001	1646		
				U.S.	PATENT DOCUMENTS			
EXAMINER INITIAL		DOCU NUMB	MENT ER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA							
	AB							
	AC							
	AD							
	AE						-	
	AF			ļ				+
	AG_							<del> </del>
	AH							
	AI							
	AJ	<del> </del>						
	AK			<u> </u>				
				FOREI	GN PATENT DOCUMENTS			
EXAMINER INITIAL		DOCU	UMENT BER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL							Ye:
								Yes
	AM	+						Yes
	AN	+-						Ye:
	AO_			<del>                                     </del>				Ye
	AP	ļ						No
			OTHER (Inc	luding Author	, Title, Date, Pertine	nt Pages, etc.	)	
	AR	11	properti virus in	7	l., "Cholesteryl-conjug ity as inhibitors of re ," Proc. Natl. Acad. So	an incarion of i	11100611 1000011	TOGETTCTCTT
	AS	11	Lowry, O	.H., et al., em. 193:265-2	"Protein Measurement wi 75, American Society of	ith the Folin I E Biological Ch	Phenol Reamemists, I	gent," J. nc. (1951).
	AT	11	Martins, enzymati	M.B.F., et a c activity,"	l., "Acylation of L-as] Biochimie 72:671-675, l	paraginase wit Elsevier Sciend	h total re ce (1990).	tention of
EXAMINER		<u> </u>	<u> </u>			DATE CO	NSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

AUG 2 8 2001

AUG 2 7 2001 TECH CENTER 1600/29002

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATION NO.
1696.0020008/RWE/BEC APPLICATIO

					May 1, 2001	1646		
				U.S.	PATENT DOCUMENTS			
EXAMINER INITIAL		DOCU NUMB		DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA							
	AB							
	AC							
	AD							<u> </u>
	AE						ļ	
	AF						<u> </u>	
	AG							
	AH	<u> </u>						<del> </del>
	AI				<del> </del>			
	AJ						<del>                                     </del>	
	AK	<u> </u>						<u> </u>
				FOREIC	ON PATENT DOCUMENTS		T	1
EXAMINER INITIAL		DOCU	MENT BER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL							Yes No
	АМ							Yes No
	AN							Yes No
	AO							Yes No
	AP							Yes No
			OTHER (Inc	luding Author	, Title, Date, Pertinent	Pages, etc.)		
	AR	12	McConahe Chlorami	y, P.J., and D ne-T Method,"	oixon, F.J., "Radioiodina Meth. Enzymol. 70:210-21	tion of Prote 3, Academic E	ins by th	e Use of the
	AS	12	Mostov, Institut	K.E., and Simi e of Technolog	ster, N.E., "Transcytosi y (1985).	s," Cell 43:3	889-390, M	lassachusetts
	AT	12	Müller, cleavage	C.E., et al., ," Int. J. Pha	"Lipophilic disulfide pr arm. 57:41-47, Elsevier S	odrugs-synthe	eses and d shers B.V.	disulfide bond (1989).
EXAMINER		<u></u>	L			DATE CONS	SIDERED	

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

AUG 2 7 2001 TECH CENTER 160072900

FORM PTO-1449

### INFORMATION DISCLOSURE STATEMENT

APPLICATION NO. 00/845,153 DOCKET NO.

APPLICANTS Shen et al.

FILING DATE

GROUP

					May 1, 2001		1646		
				v.s.	PATENT DOCUMENTS				
EXAMINER INITIAL		DOCU NUMB		DATE	NAME	CI	LASS	SUB- CLASS	FILING DATE
	AA								
	AB								
	AC								<u> </u>
	AD							ļ	
	ΑE							ļ	
	AF							<u> </u>	
	AG			<u> </u>				ļ	
	AH								
	AI							<u> </u>	
	АJ							<u> </u>	
	AK						_		
				FOREIG	N PATENT DOCUMENTS				
EXAMINER INITIAL		DOCU	MENT BER	DATE	COUNTRY	c:	LASS	SUB- CLASS	TRANSLATION
	AL								Yes No
	AM								Yes No
	AN								Yes No
	AO								Yes No
	AP								Yes No
			OTHER (Inc	luding Author	, Title, Date, Pertine	nt Pages,	etc.)		
	AR	13	Mumaniahi	, S., et al., g Hormone and	"Lipophilic Peptides: Its Biological Activit	Synthes:	is of L	auroyl Th 8:649-65	nyrotropin- 52, Plenum
	AS	13	Okahata, T, and Seki, T., "Functional capsule membranes. 10. pH-sensitive capsule membranes. Reversible permeability control from the dissociative bilayer-coated capsule membrane by an ambient pH change," Chem. Abstracts 102:391 Abstract No. 12733d, American Chemical Society (1985).						
	AT 13 Reznikoff, C.A., et al., "Establishment and Characterization of a Cloned Line of C3H Mouse Embryo Cells Sensitive to Postconfluence Inhibition of Division," Cancer Res. 33:3231-3238, American Association for Cancer Research (1973).								
EXAMINER	l		<u> </u>			DA	TE CONS	SIDERED	

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ATE DOCKET NO. 1496.0020008/RWE/BEC FIRMT & TRADE

AUG 2 8 2001 TECH CENTER 1600/2900

APPLICATION NO. 09/845,153

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

APPLICANTS Shen et al

FILING DATE

GROUP

					May 1, 2001		1646		
				U.S.	PATENT DOCUMENTS				
EXAMINER INITIAL		DOCU NUMB		DATE	NAME		CLASS	SUB- CLASS	FILING DATE
	AA								
	AB								
	AC								
	AD								
	AE								
	AF								
	AG							<u> </u>	
	AH							<u> </u>	<del> </del>
	AI							-	
	АJ							<u> </u>	
	AK							<u></u>	
				FOREI	GN PATENT DOCUMENTS				
EXAMINER INITIAL		DOCU	MENT BER	DATE	COUNTRY		CLASS	SUB- CLASS	TRANSLATION
	AL								Yes No
	AM								Yes No
	AN								Yes No
	AO								Yes No
									Ye:
	AP	_L			, Title, Date, Pert	tinent Pag	es, etc.)		
	AR	14	Reznikofi Transfort Inhibitio	f, C.A., et a.	l., "Quantitative a ned C3H Mouse Embry vision," <i>Cancer Res</i>	nd Qualita	tive Stud	lies of Ch	ITIUEIICE
	AS	Robert, S., et al., "Fatty Acid Acylation of RNase A using Reversed Micelles Microreactors," Biochem. Biophys. Res. Commun. 196:447-454, Academic Press, I (1993).							Micelles as Press, Inc.
	AT	14	I Neoglyco	nrotein Using	crophage-Directed D Leishmaniasis as t ersity of Chicago P	he Model !	Disease,"	icin Conj J. Infec	ugated to tious Dis.
EXAMINER	l		<u> </u>				DATE CON	SIDERED	

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. line through citation if not in conformance and not considered. Include copy of this form with next Draw communication to Applicant.

AUG 2 8 2001

AUG 2 7 200 TECH CENTER 1600/2900

GROUP

AUG 2 3 2001

FORM PTO-1449

### INFORMATION DISCLOSURE STATEMENT

TRADELEGE . 0020008/RWE/BEC APPLICATION NO. 09/845,153

APPLICANTS Shen et al.

FILING DATE

					May 1, 2001		1646		
				υ.	S. PATENT DOCUME	NTS			
EXAMINER INITIAL		DOCU	MENT BER	DATE	NAME		CLASS	SUB- CLASS	FILING DATE
	AA								
	AB								
	AC			L					
	AD								<del> </del>
	AE								
	AF								<u> </u>
	AG							<del> </del>	
	AH							<b>-</b>	
	AI							<u> </u>	
	AJ							<del> </del>	
	AK								<u> </u>
				FOR	EIGN PATENT DOCU	MENTS	T	T	
EXAMINER INITIAL		DOCU	JMENT BER	DATE	COUNTRY		CLASS	SUB- CLASS	TRANSLATION
	AL								Yes No
	AM								Yes No
	AN								Yes No
	AO								Yes No
									Yes No
	AP			-244 2+1	or, Title, Date,	Pertinent Pag	es, etc.)		
	AR	15	Shen, W.	-C., and Ry	ser, H.PJ., "Poperties when con ational Academy o	oly(L-lysine) h	as differ	rent membi	rane transport
	AS	15	Shen, WC., et al., "Enhancement of polypeptide and protein absorption by macromolecular carriers via endocytosis and transcytosis," Adv. Drug Deliver, Rev. 8:93-113, Elsevier Science Publishers B.V. (1992)						
	AT	<u>15</u>	Smith, 1	P.L., et al. y Rev. 8:253	, "Oral absorpti -290, Elsevier S	on of peptides cience Publish	and prote	eins," <i>Ad</i> (1992).	v. Drug
EXAMINER			<u> </u>				DATE CON	SIDERED	

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

AUG 2 3 2001
TECH CENTER 1600/2900
TECH CENTER 1600/2900
TECH CENTER 1600/2900

FORM PTO-1449

### INFORMATION DISCLOSURE STATEMENT

AT (RAGENT) NO. 1696.0020008/RWE/BEC 1PPLICATION NO 9(845,15) APPLICANTS Shen et al. GROUP

					May 1, 2001		1646		
		===		U.S.	. PATENT DOCUMENTS				
EXAMINER INITIAL	$\overline{1}$	DOCUM		DATE	NAME	CL	LASS	SUB- CLASS	FILING DATE
	AA								
	AB	<b>—</b>							
	AC	T							
	AD							<b></b>	
	AE							<b></b>	<b></b>
	AF							<u> </u>	
	AG							<b></b>	<del></del>
	АН							<del></del>	
	AI							<del> </del>	
	AJ							<del> </del>	
	AK			<u> </u>					
				FOREI	IGN PATENT DOCUMENTS			т——	
EXAMINER INITIAL		DOCU	JMENT BER	DATE	COUNTRY	CI	LASS	SUB- CLASS	TRANSLATION
	AL								Yes No
	AM								Yes No
	AN								Yes No
		+						Γ	Yes No
	AO	+-		1					Yes No
	AP	—		1 Author	r, Title, Date, Perti	inent Pages.	etc.)		
	AR	16		K., et al., n Jejunum," B	"The Transport of an Biochem. Biophys. Res	Intact Olic	gopeptio	de Across 7, Acader	; Adult nic Press,
	AS	Taub, M.E., and Shen, WC., "Polarity in the Transcytotic Processing of Apical and Basal Membrane-Bound Peroxidase-Polylysine Conjugates in MDCK Cells," J. Cell. Phys. 150:283-290, Wiley-Liss, Inc. (1992).							
	AT	<u>16</u>	Toth, I., Conjugate (1994).	, "A Novel Ch es," <i>J. Drug</i>	nemical Approach to D Targeting 2:217-239,	Orug Deliver , Harwood Ac	y: Lipi .ademic	dic Amin Publishe	o Acid rs GmbH
EXAMINER			<u> </u>			DA	TE CONS	IDERED	

FILING DATE

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

AUG 2, 8 2001 SH CENTER 1600/2900. AUG 2 7 2001 Page 17 of 22

FORM PTO-1449

### INFORMATION DISCLOSURE STATEMENT

communication to Applicant.

ABPLICATION NO. ATTY. 1696.0020008/RWE/BEC APPLICANTS Shen et al.

GROUP FILING DATE May 1, 2001 1646 U.S. PATENT DOCUMENTS EXAMINER NAME CLASS SUB-FILING DATE DATE DOCUMENT INITIAL CLASS NUMBER AΑ AB AC ΑD ΑE AF AG AΗ ΑI АJ ΑK FOREIGN PATENT DOCUMENTS EXAMINER SUB-DOCUMENT DATE COUNTRY CLASS TRANSLATION INITIAL CLASS NUMBER Yes No ALYes No MΑ Yes No AN Yes No ΑO Yes No AΡ OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Ubuka, T. et al., "Synthesis of disulfides related to glutathione and their detection in tissue," (Ganryu Aminosan) Sulfur Amino Acids 8:153-157, Ganryu AR <u>17</u> Aminosan Kenkyukai (1985). [Article in Japanese] Ubuka, T. et al., "Synthesis of disulfides related to glutathione and their detection in tissue, " Chem. Abstracts 106:728, Abstract No. 156843v, American AS <u>17</u> Chemical Society (1987). Uchimi, I. et al., "Glutathione derivatives," Chem. Abstracts 73:359, Abstract AΤ <u>17</u> No. 56440t, American Chemical Society (1970). DATE CONSIDERED EXAMINER

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next

AU6 2 3 2001

### RECEIVED

AUG 2 8 2001)

TECH CENTER 7600/2900

FORM PTO-1449

### INFORMATION DISCLOSURE STATEMENT

communication to Applicant.

Shen et al.		 
APPLICANTS		
ATTY. DOCKET NO. 1696.0020008/RWE/BEC	ADPLICATION NO.	

					May 1, 2001	1646					
				U.S	. PATENT DOCUMENTS						
EXAMINER INITIAL		DOCUI		DATE	NAME	CLASS	SUB-	FILING DATE			
	AA						- AU	122			
	AB						Degree .	20117			
	AC						+ 10	4 -			
	AD	<b>↓</b>		<del> </del>			+	1700			
	AE	-									
	AF										
	AG	<u> </u>		_							
	AH	┼									
	AI										
	AJ AK	┨──									
	IAK			FORE	IGN PATENT DOCUMENTS						
EXAMINER INITIAL		DOCU	MENT SER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION			
	AL	NOME						Yes No			
	AM							Yes No			
	AN							Yes No			
								Yes No			
	AO							Yes No			
	AP		OTHER (In	cluding Autho	or, Title, Date, Perti	nent Pages, etc.	)				
	AR	18	Hahimi	T et al. "(	Glutathione derivative Chemical Society (197	es," Chem. Abstra		3, Abstract			
	AS	18	Větvička, V., and Fornůsek, L., "Limitations Of Transmembrane Transport In Dr Delivery," <i>Crit. Rev. Ther. Drug Carrier Syst.</i> 5:141-170,CRC Press, Inc. (198								
	AT	18	Vitetta and AID	Vitetta, E., "Immunotoxins: New Therapeutic Reagents for Autoimmunity, Cancer, and AIDS," J. Clin. Immunol. 10:15S-18S, Plenum Press (1990).							
EXAMINER		<u> </u>				DATE CO	NSIDERED				
EXAMINER:	Initia ugh cita	l if i	reference If not in	considered,	whether or not citation and not considered.	on is in conformation	ance with I	MPEP 609. Dra with next			

AUG 2 3 2001

AUG 2 8 2001
TECH CENTER 1600/2900
Page 19 of 22

	ATTY. DOCKET NO. 1696.0020008/RWE/BEC	APPLICATION NO. 09/845,263
	APPLICANTS Shen et al.	7 2001
Ī	FILING DATE	GROUP 1646

DATE CONSIDERED

INFORMATION DISCLOSURE STATEMENT U.S. PATENT DOCUMENTS EXAMINER FILING DATE CLASS SUB-DATE NAME DOCUMENT INITIAL CLASS NUMBER AΑ AΒ AC ΑD ΑE AF AΗ ΑI ΑJ ΑK FOREIGN PATENT DOCUMENTS EXAMINER TRANSLATION SUB-CLASS COUNTRY DOCUMENT DATE INITIAL CLASS NUMBER Yes No ALYes MΑ Yes No AN Yes No ΑO Yes OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Wan, J., et al., "Transcellular Processing of Disulfide-and Thioether-Linked Peroxidase-Polylysine Conjugates in Cultured MDCK Epithelial Cells, " J. Cell. Phys. 145:9-15, Wiley-Liss, Inc. (1990). <u>19</u> AR Wan, J., and Shen, W.-C., "Brefeldin A and Monensin Enhance Transferrin Receptormediated Protein Transport across Epithelial Cells, " Pharm. Res. 8:S-4, Plenum AS <u>19</u> Press (1991). Wan, J., et al., "Brefeldin A Enhances Receptor-mediated Transcytosis of Transferrin in Filter-grown Madin-Darby Canine Kidney Cells, " J. Biol. Chem. AΤ <u>19</u> 267:13446-13450, American Society for Biochemistry and Molecular Biology, Inc. (1992).

FORM PTO-1449

EXAMINER

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

AUG 2 8 2001

TECH CENTER 1600/2900

AUG 2 3 2001

AUG 2 7 2001

701730

age 20 of 22

### FORM PTO-1449

### INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKRIDEN APPLICATION NO. 1696.0020008/RWE/BEC 09/845,153

APPLICANTS
Shen et al.

FILING DATE GROUP
MAY 1, 2001 1646

					May 1, 2001		1646				
				v.s.	PATENT DOCUMENTS						
EXAMINER INITIAL		DOCU	MENT ER	DATE	NAME		CLASS	SUB- CLASS	FILING DATE		
	AA										
	AB							ļ			
	AC							<u> </u>			
	AD							<u> </u>			
	AE		<u> </u>					<del> </del>			
	AF						<u> </u>	<u> </u>			
	AG						<del>                                     </del>				
	AH						<u> </u>				
	AI							<del>                                     </del>			
	AJ						<del>                                     </del>	<del> </del>			
	AK										
				FOREIG	GN PATENT DOCUMENTS		T	T			
EXAMINER INITIAL		DOCU	JMENT BER	DATE	COUNTRY		CLASS	SUB- CLASS	TRANSLATION		
	AL								Yes No		
	AM								Yes No		
	AN								Yes No		
	AO								Yes No		
	AP								Yes No		
			OTHER (Inc.	luding Author	, Title, Date, Pertin	ent Pag	es, etc.)				
	AR	20	Yavelow, Anticarci Research	nogen," <i>Cance</i>	Bowman-Birk Soybean F er Res. 43:2454s-2459s	Protease , Ameri	e Inhibito Can Assoc	er as an ciation fo	r Cancer		
o	AS	20	Intestina Acids," J	Yodoya, E., et al., "Enhanced Permeability of Tetragastrin across the Rat Intestinal Membrane and Its Reduced Degradation by Acylation with Various Fatty Acids," <i>J. Pharm. Ex. Ther. 271:</i> 1509-1513, American Society for Pharmacology and Experimental Therapeutics (1994).							
	Yoshikawa, H., et al., "Potentiation of Enteral Absorption of Human Interferon Alpha and Selective Transfer into Lymphatics in Rats," Pharm. Res. 5:249-250, Thieme Inc., (1985).										
EXAMINER			J				DATE CONS	SIDERED			
I											

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

AUG 2 8 2001 AUG 2 3 2001
TECH CENTER 1600 2 900

APPLICATION NO. ATTY. DOCKET NO. 1696.0020008/RWE/BEC FORM PTO-1449 APPLICANTS Shen et al. INFORMATION DISCLOSURE STATEMENT GROUP FILING DATE

<u> </u>	0.11.				FILING DATE May 1, 2001		1646		
					PATENT DOCUMENTS				
XAMINER NITIAL	<del> </del>	DOCUM	1ENT	DATE	NAME	CL	ASS	SUB-	FILING DATE
NIIIAL		NUMBE						CLASS	
	AA								
	AB	<u> </u>							<del> </del>
	AC	<u> </u>							<del>                                     </del>
	AD	<u> </u>							
	AE								
	AF								
	AG			<u> </u>					
	HA								1
	ΑI								
	AJ								
	AK							<u> </u>	
				FOREI	ON PATENT DOCUMENTS			T	
EXAMINER INITIAL		DOCUMENT NUMBER		DATE	COUNTRY	CI	ASS	SUB- CLASS	TRANSLATION
		NOME	EK	1					Yes
	AL							+	No
				ļ					Yes No
	AM_						-		Yes
	AN			<del> </del>					Yes
	AO								Ye
	AP								No
			OTHER (Inc	cluding Author	, Title, Date, Perti	inent Pages,	etc.)		
	AR	21	"Protein Gove, Ph (1971).	," <i>In:</i> Webste: D., ed. G. & (	r's Third New Intern C. Merriam Co. Sprin	ational Dict gfield, Mass	tionary sachuse	, Unabri etts, USA	dged, P.B. p. 1823
AS 21 Patent Abstract of Japanese Publication No. 63246382, obtained from the Europe Patent Office.								n the European	
	AT	21	Suppleme	entary Europea	n Search Report of E	EP 96 90 369	0, mai	led Marc	n 5, 1998.
						DA	TE CON	SIDERED	
EXAMINER						1			

EXAMINER

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

AUG 2 8 2001

TECH CENTER 1600/2900

Page 22 of 22 APPLICATION NO. 09/845,153

FORM PTO-1449

### INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1696.0020008/RWE/BEC

APPLICANTS Shen et al. AUG & 7 2001

INE	FORMATION	DISCI	JOSURE SIA	I EMEN I	FILING DATE May 1, 2001	GROUP	-	
				v.s.	PATENT DOCUMENTS		7700	
EXAMINER INITIAL		DOCUM NUMBE		DATE	NAME .	CLASS	SUB- CLASS	FILING DATE
	AA							
	AB							
	AC							
	AD						<del> </del>	
	AE					<u> </u>	<del> </del>	
	AF	ļ						
	AG	<u> </u>				<u> </u>		
	AH	ļ				<del> </del>		
	AI	ļ					<u> </u>	
	AJ	<del>                                     </del>					<u> </u>	
	AK				N PATENT DOCUMENTS	<b>L</b>	1	
		1		FOREIG	N PATENT DOCUMENTS	1	T	
EXAMINER INITIAL	į	DOCUI		DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL							Yes No
	7.4							Yes No
	AM	1						Yes No
	AN							Yes No
	AP				-			Yes No
	, AL		THER (Inc)	uding Author,	Title, Date, Pertinent Pag	ges, etc.)		
	AR	22			e: File Registry, RN 23130-			
	AS	22						
	AT	22						
EXAMINER						DATE CONS	IDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.